Seattle Genetics' stock price fell to $19.17 in pre-market trading despite yesterday's expert panel recommendation accelerated approval of the company's drug, brentuximab vedotin (Adcetris). Investors are apparently concerned that the FDA may ask for more data about the drug's benefits given the fact that the developer only conducted two small trials for the blood cancer drug. The developer's stock dropped to $18.81 after the market opened. Story